Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 04, 2023

Association Between Invasive Disease–Free Survival and Biomarkers in Patients With Residual Invasive Breast Cancer After Neoadjuvant Therapy

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Biomarker Data From the Phase III KATHERINE Study of Adjuvant T-DM1 Versus Trastuzumab for Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer
Clin. Cancer Res 2023 Feb 02;[EPub Ahead of Print], C Denkert, C Lambertini, PA Fasching, KL Pogue-Geile, MS Mano, M Untch, N Wolmark, CS Huang, S Loibl, EPP Mamounas, CE Geyer, PC Lucas, T Boulet, C Song, GD Lewis, M Nowicka, S de Haas, M Basik

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading